Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity
Background Targeted treatment of chronic myelogenous leukemia using imatinib has dramatically improved patient outcome. However, residual disease can be detected in the majority of patients treated with imatinib. Compensatory activation of MAP kinases (MAPK1/2) in response to BCR-ABL-inhibitors has...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2012
|
| In: |
Journal of cancer research and clinical oncology
Year: 2011, Jahrgang: 138, Heft: 2, Pages: 203-212 |
| ISSN: | 1432-1335 |
| DOI: | 10.1007/s00432-011-1086-x |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1007/s00432-011-1086-x Verlag, Volltext: http://link.springer.com/10.1007/s00432-011-1086-x 
|
| Verfasserangaben: | Nicolai Härtel, Thomas Klag, Benjamin Hanfstein, Martin C. Mueller, Thomas Schenk, Philipp Erben, Andreas Hochhaus, Paul La Rosée |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1572339721 | ||
| 003 | DE-627 | ||
| 005 | 20230426124258.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180424r20122011xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00432-011-1086-x |2 doi | |
| 035 | |a (DE-627)1572339721 | ||
| 035 | |a (DE-576)502339721 | ||
| 035 | |a (DE-599)BSZ502339721 | ||
| 035 | |a (OCoLC)1341007584 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Härtel, Nicolai |d 1977- |e VerfasserIn |0 (DE-588)129912913 |0 (DE-627)483650609 |0 (DE-576)297899821 |4 aut | |
| 245 | 1 | 0 | |a Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells |b a potential mechanism of altered leukemogenicity |c Nicolai Härtel, Thomas Klag, Benjamin Hanfstein, Martin C. Mueller, Thomas Schenk, Philipp Erben, Andreas Hochhaus, Paul La Rosée |
| 264 | 1 | |c 2012 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 17 November 2011 | ||
| 500 | |a Gesehen am 24.04.2018 | ||
| 520 | |a Background Targeted treatment of chronic myelogenous leukemia using imatinib has dramatically improved patient outcome. However, residual disease can be detected in the majority of patients treated with imatinib. Compensatory activation of MAP kinases (MAPK1/2) in response to BCR-ABL-inhibitors has been reported as a potential cytokine-dependent resistance mechanism leading to the rescue of leukemic progenitor cells. | ||
| 534 | |c 2011 | ||
| 700 | 1 | |a Hanfstein, Benjamin |d 1971- |e VerfasserIn |0 (DE-588)143353519 |0 (DE-627)645128228 |0 (DE-576)336605587 |4 aut | |
| 700 | 1 | |a Müller, Martin Christian |d 1972- |e VerfasserIn |0 (DE-588)121360296 |0 (DE-627)705409236 |0 (DE-576)181482819 |4 aut | |
| 700 | 1 | |a Erben, Philipp |d 1973- |e VerfasserIn |0 (DE-588)128501014 |0 (DE-627)373920997 |0 (DE-576)297181661 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cancer research and clinical oncology |d Berlin : Springer, 1979 |g 138(2012), 2, Seite 203-212 |h Online-Ressource |w (DE-627)253769515 |w (DE-600)1459285-X |w (DE-576)072578319 |x 1432-1335 |7 nnas |a Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells a potential mechanism of altered leukemogenicity |
| 773 | 1 | 8 | |g volume:138 |g year:2012 |g number:2 |g pages:203-212 |g extent:10 |a Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells a potential mechanism of altered leukemogenicity |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00432-011-1086-x |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://link.springer.com/10.1007/s00432-011-1086-x |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180424 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 128501014 |a Erben, Philipp |m 128501014:Erben, Philipp |d 60000 |d 63100 |e 60000PE128501014 |e 63100PE128501014 |k 0/60000/ |k 1/60000/63100/ |p 6 | ||
| 998 | |g 121360296 |a Müller, Martin Christian |m 121360296:Müller, Martin Christian |d 60000 |d 61200 |e 60000PM121360296 |e 61200PM121360296 |k 0/60000/ |k 1/60000/61200/ |p 4 | ||
| 998 | |g 143353519 |a Hanfstein, Benjamin |m 143353519:Hanfstein, Benjamin |d 60000 |d 61200 |e 60000PH143353519 |e 61200PH143353519 |k 0/60000/ |k 1/60000/61200/ |p 3 | ||
| 998 | |g 129912913 |a Härtel, Nicolai |m 129912913:Härtel, Nicolai |d 60000 |d 61200 |e 60000PH129912913 |e 61200PH129912913 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1572339721 |e 3007028760 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1007/s00432-011-1086-x"],"eki":["1572339721"]},"physDesc":[{"extent":"10 S."}],"relHost":[{"title":[{"title_sort":"Journal of cancer research and clinical oncology","title":"Journal of cancer research and clinical oncology","subtitle":"official organ of the Deutsche Krebsgesellschaft"}],"language":["eng","ger"],"part":{"volume":"138","text":"138(2012), 2, Seite 203-212","year":"2012","issue":"2","extent":"10","pages":"203-212"},"pubHistory":["Volume 93, issue 1 (January 1979)-"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells a potential mechanism of altered leukemogenicityJournal of cancer research and clinical oncology","id":{"zdb":["1459285-X"],"issn":["1432-1335"],"eki":["253769515"]},"note":["Gesehen am 19.03.25","Teils ungezählte Beil.: Supplement"],"origin":[{"publisherPlace":"Berlin ; Heidelberg","publisher":"Springer","dateIssuedDisp":"1979-","dateIssuedKey":"1979"}],"recId":"253769515","type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"Cancer research and clinical oncology"}]}],"note":["Published online: 17 November 2011","Gesehen am 24.04.2018"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1572339721","origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"2012"}],"person":[{"family":"Härtel","given":"Nicolai","role":"aut","display":"Härtel, Nicolai"},{"role":"aut","given":"Benjamin","display":"Hanfstein, Benjamin","family":"Hanfstein"},{"role":"aut","given":"Martin Christian","display":"Müller, Martin Christian","family":"Müller"},{"family":"Erben","display":"Erben, Philipp","given":"Philipp","role":"aut"}],"name":{"displayForm":["Nicolai Härtel, Thomas Klag, Benjamin Hanfstein, Martin C. Mueller, Thomas Schenk, Philipp Erben, Andreas Hochhaus, Paul La Rosée"]},"title":[{"title_sort":"Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells","title":"Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells","subtitle":"a potential mechanism of altered leukemogenicity"}],"language":["eng"]} | ||
| SRT | |a HAERTELNICENHANCEDAB2012 | ||